![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
CTMX CytomX
- 0.796
- -0.030-3.63%
Close Feb 14 16:00 ET
- 0.797
- +0.001+0.09%
Post 20:01 ET
62.32MMarket Cap4.98P/E (TTM)
0.844High0.788Low885.37KVolume0.827Open0.826Pre Close716.07KTurnover1.23%Turnover RatioLossP/E (Static)78.26MShares5.85052wk High-2.65P/B57.52MFloat Cap0.75052wk Low--Dividend TTM72.24MShs Float35.000Historical High--Div YieldTTM6.79%Amplitude0.750Historical Low0.808Avg Price1Lot Size
CytomX Stock Forum
Sign in to post a comment
$CytomX (CTMX.US)$ 18% pre market?
2
$CytomX (CTMX.US)$
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
Monday, 6th January at 4:05 pm
- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 -
- Early-stage research and platform capabilities to be concentrated on existing and potential future partnerships dur...
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
Monday, 6th January at 4:05 pm
- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 -
- Early-stage research and platform capabilities to be concentrated on existing and potential future partnerships dur...
$CytomX (CTMX.US)$ CytomX Therapeutics: Ended 3Q With $117.6M of Cash, Cash Equivalents and Investments >CTMX
Dow Jones· 1 min ago
Dow Jones· 1 min ago
3
4
$CytomX (CTMX.US)$ this stock is undervalued.🚀🚀🚀
$CytomX (CTMX.US)$ CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference! December 4 at 8AM est!
1
Note: This seems to be a long list. The rationale is that I al focused on at least 20% gains and not just after bangers. My trading style is to compound those 10-15-20-30% earnings and roll all profit rather than waiting for runners everyday. If runners appear, then I’ll grab it as well. Each has his own style earning.
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
35
19
5
$CytomX (CTMX.US)$ $Onconetix (ONCO.US)$ $Edesa Biotech (EDSA.US)$ $XBP Europe Holdings (XBP.US)$ $Nauticus Robotics (KITT.US)$ $Alset (AEI.US)$ $Carmell (CTCX.US)$ $Jayud Global Logistics Ltd. (JYD.US)$ $Vir Biotechnology (VIR.US)$ $Shimmick (SHIM.US)$ $Credo Technology (CRDO.US)$ $Janux Therapeutics (JANX.US)$ $Citius Oncology (CTOR.US)$ $Volato Group (SOAR.US)$
📊⚡️📊
📊⚡️📊
3
7
1
$CytomX (CTMX.US)$
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
1
$CytomX (CTMX.US)$ Volumn is very low but rising slowly. Interesting
No comment yet
Trending Stocks
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!
HW win win : This is just a return to the original price, he has been hovering around 1.03.
watuzzi OP HW win win : just enough not to get delisted